Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Visceral pain threshold represents the minimum intensity of a stimulus applied to internal organs—such as the esophagus, stomach, or colon—that is perceived as painful by an individual. It is a physiological measurement rather than a single molecular target, though it is governed by a complex network of receptors and ion channels including TRPV1, Nav1.7, and various opioid receptors [2][3]. In many clinical conditions, particularly functional gastrointestinal disorders like irritable bowel syndrome (IBS), patients exhibit a decreased visceral pain threshold, a state known as visceral hypersensitivity [1]. This hypersensitivity leads to significant morbidity as normal physiological processes, like digestion, are perceived as painful. Therapeutic strategies focus on increasing this threshold by targeting peripheral afferent signaling or central processing pathways to provide symptomatic relief [3][4].
Drugs modulate this threshold by acting on specific molecular targets such as guanylate cyclase-C (GC-C), opioid receptors, or ion channels (e.g., calcium or sodium channels) to reduce the excitability of visceral afferent nerves [1][2].
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Visceral pain threshold (VPT).